Attainment of LLDAS in those achieving an SRI-4 response in BLISS-52 and BLISS-76
| BLISS-52 | ||||
| All groups (%) | Placebo (%) | Belimumab 1 mg/kg (%) | Belimumab10 mg/kg (%) | |
| SRI-4+/LLDAS+ | 13.8 | 9.7 | 13.7 | 17.0 |
| SRI-4−/LLDAS- | 96.7 | 99.0 | 93.5 | 97.4 |
| LLDAS−/SRI-4+ | 59.1 | 52.8 | 59.4 | 64.9 |
| LLDAS+/SRI-4- | 8.7 | 7.7 | 23.1 | 6.7 |
| BLISS-76 | ||||
| All groups (%) | Placebo (%) | Belimumab 1 mg/kg (%) | Belimumab 10 mg/kg (%) | |
| SRI-4+/LLDAS+ | 17.7 | 14.8 | 18.3 | 19.3 |
| SRI-4−/LLDAS- | 95.2 | 98.1 | 95.2 | 91.0 |
| LLDAS−/SRI-4+ | 47.1 | 42.1 | 46.4 | 53.2 |
| LLDAS+/SRI-4- | 20.6 | 13.3 | 20.8 | 24.1 |
*+Attained outcome measure.
†-Did not attain outcome measure.
LLDAS, Lupus Low Disease Activity State; SRI-4, Systemic Lupus Erythematosus Responder Index-4.